Associations of Coagulation Factor V Leiden and Prothrombin G20210A Mutations With Budd-Chiari Syndrome and Portal Vein Thrombosis: A Systematic Review and Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 11, 2014, Pages 1801-1812.e7

  Qi, Xingshun ^a,b   Ren, Weirong ^a   De Stefano, Valerio ^c   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Gastroenterology Hospital of Chinese People's Liberation Army   (China)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Blood; Genetic; Risk Factor; Venous Thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; BLOOD CLOTTING FACTOR 5;

ACUTE PANCREATITIS; ANTICOAGULATION; BIBLIOGRAPHIC DATABASE; BUDD CHIARI SYNDROME; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; GENE MUTATION; HUMAN; KIDNEY VEIN THROMBOSIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; META ANALYSIS; PORTAL VEIN OBSTRUCTION; PORTAL VEIN THROMBOSIS; PREVALENCE; QUALITY CONTROL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; BUDD-CHIARI SYNDROME; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MUTATION; PATHOLOGY; PORTAL VEIN; THROMBOSIS;

BUDD-CHIARI SYNDROME; FACTOR V; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PORTAL VEIN; PROTHROMBIN; THROMBOSIS;

EID: 84908248996     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.04.026     Document Type: Review

References (76)

1. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
2. Voorberg J., Roelse J., Koopman R., et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994, 343:1535-1536.
3. Greengard J.S., Sun X., Xu X., et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994, 343:1361-1362.
4. Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995, 74:139-148.
5. Poort S.R., Rosendaal F.R., Reitsma P.H., et al. Acommon genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88:3698-3703.
6. Simone B., De Stefano V., Leoncini E., et al. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetetrahydrofolate reductase C677T: a meta-analysis involving over 11,000cases and 21,000 controls. Eur J Epidemiol 2013, 28:621-647.
7. Emmerich J., Rosendaal F.R., Cattaneo M., et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001, 86:809-816.
8. Segal J.B., Brotman D.J., Necochea A.J., et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009, 301:2472-2485.
9. Vandenbroucke J.P., Koster T., Briet E., et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994, 344:1453-1457.
10. De Stefano V., Martinelli I., Mannucci P.M., et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. NEngl J Med 1999, 341:801-806.
11. Marchiori A., Mosena L., Prins M.H., et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007, 92:1107-1114.
12. De Stefano V., Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the guidelines from scientific societies and working groups. Thromb Haemost 2013, 110:697-705.
13. De Stefano V., Rossi E., Paciaroni K., et al. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002, 87:1095-1108.
14. DeLeve L.D., Valla D.C., Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009, 49:1729-1764.
15. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
16. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. JNatl Cancer Inst 1959, 22:719-748.
17. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
18. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
19. Amitrano L., Brancaccio V., Guardascione M.A., et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000, 31:345-348.
20. Amitrano L., Brancaccio V., Guardascione M.A., et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy 2002, 34:535-538.
21. Amitrano L., Guardascione M.A., Ames P.R.J., et al. Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. Thromb Haemost 2006, 95:221-223.
22. Colaizzo D., Tiscia G.L., Bafunno V., et al. The JAK2 rs12343867 CC genotype frequently occurs in patients with splanchnic venous thrombosis without the JAK2V617F mutation: a retrospective study. JThromb Haemost 2010, 8:413-416.
23. Salama K., El-Koofy N., El-Hawary M., et al. Thrombophilic factors in Egyptian children with portal vein thrombosis. Indian J Gastroenterol 2007, 26:252-253.
24. Pasta L., Marrone C., D'Amico M., et al. MTHFR C677T homozygous as risk factor for complications after OLT for cryptogenic cirrhosis. Clin Transplant 2006, 20:796-798.
25. Pereboom I.T.A., Adelmeijer J., Van Der Steege G., et al. Prothrombotic gene polymorphisms: possible contributors to hepatic artery thrombosis after orthotopic liver transplantation. Transplantation 2011, 92:587-593.
26. Rebours V., Boudaoud L., Vullierme M.P., et al. Extrahepatic portal venous system thrombosis in recurrent acute and chronic alcoholic pancreatitis is caused by local inflammation and not thrombophilia. Am J Gastroenterol 2012, 107:1579-1585.
27. Balta G., Altay C., Gurgey A. PAI-1 gene 4G/5G genotype: a risk factor for thrombosis in vessels of internal organs. Am J Hematol 2002, 71:89-93.
28. Gurney D., Lip G.Y.H., Blann A.D. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002, 70:126-132.
29. Spiezia L., Abalotti C., Rossetto V., et al. Splanchnic venous thrombosis and thrombophilia: a case-control study. Pathophysiol Haemost Thromb 2010, 37:A119.
30. Abdel Ghaffar T.Y., Elsayed S.M., Sakr M.A., et al. Factor V G1691A (Leiden) is a major etiological factor in Egyptian Budd-Chiari syndrome patients. Turk J Hematol 2011, 28:299-305.
31. Colak Y., Karasu Z., Oruc N., et al. Hyperhomocysteinaemia and factor V Leiden mutation are associated with Budd-Chiari syndrome. Eur J Gastroenterol Hepatol 2006, 18:917-920.
32. Feng B., Xu K., Jiang H. Relationship between factor V Leiden mutation and Chinese Budd-Chiari syndrome and its clinical significance. Zhonghua Yi Xue Za Zhi 2000, 80:354-357.
33. Kumar S.I., Kumar A., Srivastava S., et al. Low frequency of factor V Leiden and prothrombin G20210A mutations in patients with hepatic venous outflow tract obstruction in northern India: a case-control study. Indian J Gastroenterol 2005, 24:211-215.
34. Lin G.L., Xu P.Q., Qi H., et al. Relations of Budd-Chiari syndrome to prothrombin gene mutation. Hepatobiliary Pancreat Dis Int 2004, 3:214-218.
35. Bhattacharyya M., Makharia G., Kannan M., et al. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol 2004, 121:844-847.
36. Heller C., Schobess R., Kurnik K., et al. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors-a multicentre case-control study. For the Childhood Thrombophilia Study Group. Br J Haematol 2000, 111:534-539.
37. Janssen H.L.A., Meinardi J.R., Vleggaar F.P., et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000, 96:2364-2368.
38. Mahmoud A.E.A., Elias E., Beauchamp N., et al. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997, 40:798-800.
39. Pasta L., Marrone C., D'Amico M., et al. MTHFR C677T and other inherited coagulation disorders in Budd Chiari syndrome (BCS) and portal vein thrombosis (PVT) with or without liver cirrhosis (LC). JHepatol 2005, 42(Suppl 2):85.
40. De Santis A., Cristofari F., Gigliotti F., et al. Inherited coagulation disorders in cirrhotic patients with and without portal vein thrombosis (PVT). Dig Liver Dis 2005, 37:A42.
41. Amitrano L., Guardascione M.A., Brancaccio V., et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. JHepatol 2004, 40:736-741.
42. Mangia A., Villani M.R., Cappucci G., et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005, 17:745-751.
43. Maras J.S., Garg V., Sarin S.K. MTHFR C677T, prothrombin G20210A and JAK2 V617F mutations are associated with increased risk of portal vein thrombosis in patients with chronic liver disease. Hepatology 2010, 52:904A.
44. Pellicelli A.M., D'Ambrosio C., Barbaro G., et al. Clinical and genetic factors associated to development of portal vein thrombosis in cirrhotic patients without hepatocellular carcinoma. JHepatol 2011, 54:S77.
45. Erkan O., Bozdayi A.M., Disibeyaz S., et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005, 17:339-343.
46. Amitrano L., Guardascione M.A., Brancaccio V., et al. Inherited thrombophilic disorders in patients with portal vein thrombosis. JHepatol 2000, 32(Suppl 2):133.
47. Chamouard P., Pencreach E., Maloisel F., et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999, 116:144-148.
48. Colaizzo D., Amitrano L., Tiscia G.L., et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. JThromb Haemost 2007, 5:55-61.
49. El-Karaksy H., El-Koofy N., El-Hawary M., et al. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hematol 2004, 83:712-715.
50. Koshy A., Jeyakumari M., Factor V. Leiden is not commonly associated with idiopathic portal vein thrombosis in Southern India. Indian J Gastroenterol 2006, 25:140-142.
51. Koshy A., Jeyakumari M. Prothrombin G20210A gene variant is not associated with idiopathic portal vein thrombosis in an area endemic for portal vein thrombosis. Ann Hematol 2006, 85:126-128.
52. Pinto R.B., Silveira T.R., Bandinelli E., et al. Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders. JPediatr Surg 2004, 39:1356-1361.
53. Primignani M., Martinelli I., Bucciarelli P., et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005, 41:603-608.
54. Seixas C.A., Hessel G., Ribeiro C.C., et al. Factor V Leiden is not common in children with portal vein thrombosis. Thromb Haemost 1997, 77:258-261.
55. Shah S.R., DasGupta A., Sharma A., et al. Thrombophilic conditions in non-cirrhotic portal vein thrombosis. Indian J Gastroenterol 2005, 24:205-210.
56. Sharma S., Kumar S.I., Poddar U., et al. Factor V Leiden and prothrombin gene G20210A mutations are uncommon in portal vein thrombosis in India. Indian J Gastroenterol 2006, 25:236-239.
57. Dentali F., Galli M., Gianni M., et al. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. A meta-analysis. Thromb Haemost 2008, 99:675-682.
58. Samonakis D.N., Koutroubakis I.E., Sfiridaki A., et al. Hypercoagulable states in patients with hepatocellular carcinoma. Dig Dis Sci 2004, 49:854-858.
59. Zocco M.A., Di Stasio E., De Cristofaro R., et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. JHepatol 2009, 51:682-689.
60. Barcellona D., Fenu L., Cauli C., et al. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. Thromb Haemost 2003, 90:1061-1064.
61. Condat B., Pessione F., Hillaire S., et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001, 120:490-497.
62. Spaander M.C.W., Hoekstra J., Hansen B.E., et al. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. JThromb Haemost 2013, 11:452-459.
63. Plessier A., Darwish-Murad S., Hernandez-Guerra M., et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010, 51:210-218.
64. Darwish Murad S., Plessier A., Hernandez-Guerra M., et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009, 151:167-175.
65. Northup P.G., Sundaram V., Fallon M.B., et al. Hypercoagulation and thrombophilia in liver disease. JThromb Haemost 2008, 6:2-9.
66. Tripodi A., Anstee Q.M., Sogaard K.K., et al. Hypercoagulability in cirrhosis: causes and consequences. JThromb Haemost 2011, 9:1713-1723.
67. Assy N., Bekirov I., Mejritsky Y., et al. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2005, 11:5834-5839.
68. Papatheodoridis G.V., Papakonstantinou E., Andrioti E., et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003, 52:404-409.
69. Lee H.M., Amin M., Kaplan M.M., et al. Reversible hepatic decompensation in primary biliary cirrhosis due to hypercoagulability. Ann Intern Med 2007, 147:675.
70. Villa E., Camma C., Marietta M., et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012, 143:1253-1260. e1-4.
71. Rossi E., Za T., Ciminello A., et al. The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia. Thromb Haemost 2008, 99:1030-1034.
72. Mäkelburg A.B., Veeger N.J., Middeldorp S., et al. Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. Haematologica 2010, 95:1030-1033.
73. Dentali F., Ageno W., Bozzato S., et al. Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a meta-analysis of the literature. JThromb Haemost 2012, 10:732-737.
74. Qi X., Wu F., Ren W., et al. Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. Thromb Haemost 2013, 109:878-884.
75. De Stefano V., Chiusolo P., Paciaroni K., et al. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998, 24:367-379.
76. Hessner M.J., Luhm R.A., Pearson S.L., et al. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost 1999, 81:733-738.